## Dan Kibuule

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5701869/publications.pdf

Version: 2024-02-01

393982 377514 1,371 63 19 34 citations h-index g-index papers 64 64 64 1328 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Response to the Novel Corona Virus (COVID-19) Pandemic Across Africa: Successes, Challenges, and Implications for the Future. Frontiers in Pharmacology, 2020, 11, 1205.	1.6	143
2	Ongoing strategies to improve the management of upper respiratory tract infections and reduce inappropriate antibiotic use particularly among lower and middle-income countries: findings and implications for the future. Current Medical Research and Opinion, 2020, 36, 301-327.	0.9	111
3	Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries. Life, 2021, 11, 528.	1.1	95
4	Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future. Frontiers in Pharmacology, 2020, 11, 108.	1.6	79
5	Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. Cardiovascular Drugs and Therapy, 2017, 31, 565-578.	1.3	68
6	Compliance to guidelines for the prescribing of antibiotics in acute infections at Namibia's national referral hospital: a pilot study and the implications. Expert Review of Anti-Infective Therapy, 2017, 15, 713-721.	2.0	62
7	Validity of World Health Organisation prescribing indicators in Namibia's primary healthcare: findings and implications. International Journal for Quality in Health Care, 2019, 31, 338-345.	0.9	61
8	Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring. European Journal of Clinical Pharmacology, 2016, 72, 905-916.	0.8	58
9	Antibiotic use in acute respiratory infections in under-fives in Uganda: findings and implications. Expert Review of Anti-Infective Therapy, 2016, 14, 863-872.	2.0	47
10	Fixed dose drug combinations $\hat{a}\in$ are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 1-26.	0.7	47
11	Compliance to prescribing guidelines among public health care facilities in Namibia; findings and implications. International Journal of Clinical Pharmacy, 2020, 42, 1227-1236.	1.0	43
12	Rapid Assessment of the Potential Paucity and Price Increases for Suggested Medicines and Protection Equipment for COVID-19 Across Developing Countries With a Particular Focus on Africa and the Implications. Frontiers in Pharmacology, 2020, 11, 588106.	1.6	41
13	Pharmacotherapeutic interventions for bipolar disorder type II: addressing multiple symptoms and approaches with a particular emphasis on strategies in lower and middle-income countries. Expert Opinion on Pharmacotherapy, 2019, 20, 2237-2255.	0.9	38
14	Ongoing and planned activities to improve the management of patients with Type 1 diabetes across Africa; implications for the future. Hospital Practice (1995), 2020, 48, 51-67.	0.5	33
15	Challenges and Innovations Brought about by the COVID-19 Pandemic Regarding Medical and Pharmacy Education Especially in Africa and Implications for the Future. Healthcare (Switzerland), 2021, 9, 1722.	1.0	33
16	Impact of COVID-19 pandemic on pharmaceutical systems and supply chain – a phenomenological study. Exploratory Research in Clinical and Social Pharmacy, 2021, 2, 100037.	0.6	30
17	Evidence-based public policy making for medicines across countries: findings and implications for the future. Journal of Comparative Effectiveness Research, 2021, 10, 1019-1052.	0.6	30
18	Awareness of, responsiveness to and practice of patients' rights at Uganda's national referral hospital. African Journal of Primary Health Care and Family Medicine, 2013, 5, .	0.3	25

#	Article	IF	CITATIONS
19	An analysis of policies for cotrimoxazole, amoxicillin and azithromycin use in Namibia's public sector: Findings and therapeutic implications. International Journal of Clinical Practice, 2017, 71, e12918.	0.8	23
20	Assessment of multidrug-resistant tuberculosis (MDR-TB) treatment outcomes in Sudan; findings and implications. Expert Review of Anti-Infective Therapy, 2019, 17, 927-937.	2.0	23
21	Multidisciplinary and multisectoral coalitions as catalysts for action against antimicrobial resistance: Implementation experiences at national and regional levels. Global Public Health, 2018, 13, 1781-1795.	1.0	20
22	Predictors of Multidrug-Resistant Tuberculosis (MDR-TB) in Sudan. Antibiotics, 2019, 8, 90.	1.5	20
23	Prevalence of self-medication for acute respiratory infections in young children in namibia: Findings and implications. Journal of Research in Pharmacy Practice, 2019, 8, 220.	0.2	20
24	Initiatives Across Countries to Reduce Antibiotic Utilisation and Resistance Patterns: Impact and Implications., 2017,, 539-576.		19
25	Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia. International Journal of Tuberculosis and Lung Disease, 2019, 23, 441-449.	0.6	17
26	Liver enzyme elevations in a cohort of HIV/AIDS patients on first-line antiretroviral therapy in Namibia: Findings and implications. Alexandria Journal of Medicine, 2018, 54, 49-56.	0.4	15
27	Predictors of tuberculosis treatment success under the DOTS program in Namibia. Expert Review of Respiratory Medicine, 2018, 12, 979-987.	1.0	12
28	Effective integration of pharmacovigilance systems at public health facilities in resource-limited settings: A qualitative study. Research in Social and Administrative Pharmacy, 2020, 16, 1111-1116.	1.5	11
29	Initiatives to increase the prescribing of low cost generics; the case of Scotland in the international context. Medical Research Archives, 2017, 5, .	0.1	11
30	An assessment of Makerere University College of Health Sciences: optimizing health research capacity to meet Uganda's priorities. BMC International Health and Human Rights, 2011, 11, S12.	2.5	10
31	Effectiveness of antibiotic stewardship programmes in primary health care settings in developing countries. Research in Social and Administrative Pharmacy, 2020, 16, 1309-1313.	1.5	10
32	Essential and forgotten antibiotics: An inventory in low- and middle-income countries. International Journal of Antimicrobial Agents, 2019, 54, 273-282.	1.1	9
33	Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia. ERJ Open Research, 2020, 6, 00030-2019.	1.1	8
34	Quality assurance of health management information system in Kayunga district, Uganda. African Evaluation Journal, 2018, 6, .	0.7	8
35	Isoniazid acetylation phenotypes in the Sudanese population; findings and implications. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2019, 17, 100120.	0.6	7
36	Optimizing spontaneous adverse drug reaction reporting in public healthcare setting in Namibia. Basic and Clinical Pharmacology and Toxicology, 2020, 126, 247-253.	1,2	6

#	Article	IF	Citations
37	COVID-19, health care and self-medication issues in resource-limited settings: Findings and implications based on experiences in Ghana. Advances in Human Biology, 2021, 11, 224.	0.1	6
38	Optimizing data quality of pharmaceutical information systems in public health care in resource limited settings. Research in Social and Administrative Pharmacy, 2020, 16, 828-835.	1.5	5
39	A cost-effective model for monitoring medicine use in Namibia: outcomes and implications. African Evaluation Journal, 2017, 5, .	0.7	5
40	Household management of acute respiratory infections in children under five years in Kampala Uganda. African Journal of Pharmacy and Pharmacology, 2015, 9, 730-737.	0.2	4
41	Antipseudomonal potential of Colophospermum mopane and Acrotome inflata, medicinal plants indigenous to Namibia. African Journal of Pharmacy and Pharmacology, 2017, 11, 78-86.	0.2	4
42	Health workforce planning in Namibia: assessing a pilot workforce survey of pharmacists. International Journal of Pharmacy Practice, 2019, 27, 565-574.	0.3	4
43	Implications of antibiotic exposure among children in low-income and middle-income countries. Lancet Infectious Diseases, The, 2020, 20, 146-147.	4.6	4
44	A model to strengthen utility of quality pharmaceutical health systems data in resource-limited settings. Medicine Access Point of Care, 2020, 4, 239920262094026.	1.0	4
45	Clinical Significance of the Plasma Protein Binding of Rifampicin in the Treatment of Tuberculosis Patients. Clinical Pharmacokinetics, 2019, 58, 1511-1515.	1.6	3
46	Compliance to hypertensive prescribing guidelines and blood pressure control in elderly patients in Namibia: findings and implications. Journal of Pharmaceutical Health Services Research, 2021, 12, 53-60.	0.3	3
47	Incorporating pharmaceutical supply management modules in the pre-service curriculum of the BPharm program, of the University of Namibia, School of Pharmacy. Journal of Pharmaceutical Policy and Practice, 2014, 7, .	1.1	2
48	VP25 African Countries Are Working Together To Enhance Medicine Use. International Journal of Technology Assessment in Health Care, 2017, 33, 157-158.	0.2	2
49	Alignment of standard treatment guidelines with medicine use indicators in a limitedâ€resource setting: findings and implications. Journal of Pharmaceutical Health Services Research, 2020, 11, 149-157.	0.3	2
50	RESEARCH ARTICLE: Emergency compounding of COVID-19 medicines: A readiness programme to up-skill pharmacy graduates in Namibia. Pharmacy Education, 0, , 117-123.	0.2	2
51	Assessing smoking cessation services and pharmacotherapy in Namibia: findings and implications for future policy initiatives. Expert Review of Pharmacoeconomics and Outcomes Research, 2022, 22, 699-710.	0.7	2
52	Prevalence and determinants of pesticide use in informal households in Mulago II parish, Kampala Uganda. Journal of Toxicology and Environmental Health Sciences, 2015, 7, 52-59.	0.6	1
53	Does pharmaceutical information systems data inform decision-making in public healthcare? Utility of a national system in a limited resource setting. Research in Social and Administrative Pharmacy, 2020, 16, 1526-1534.	1.5	1
54	EDITORIAL: COVID-19: Rebooting pharmacy education in resource-limited settings. Pharmacy Education, 0, , 67-70.	0.2	1

## DAN KIBUULE

#	Article	IF	CITATIONS
55	COVID-19 resilient pharmacy education: A grassroots work-integrated programme to strengthen the pharmaceutical workforce in Namibia. Pharmacy Education, 0, , 205-211.	0.2	1
56	Migration to online pharmacy education in Namibia: Successes, challenges and competence implications. Pharmacy Education, 0, , 174-182.	0.2	1
57	National standard treatment guidelines: their impact on medicine use indicators in a resource-limited setting. Journal of Pharmaceutical Health Services Research, 2021, 12, 61-68.	0.3	1
58	An analysis of hospital pharmacy practice in Namibia, based on FIP's Basel Statements. International Journal of Pharmacy Practice, 2021, 29, 350-355.	0.3	1
59	Consumption of psychotropic medicines at a referral hospital Namibia: findings and implications. African Health Sciences, 2020, 20, 1000-1010.	0.3	1
60	Developing a grass-roots method for monitoring medicines shortages in southern Africa: Report of a pilot in Namibia. Research in Social and Administrative Pharmacy, 2020, 16, 1294-1297.	1.5	0
61	Utility of medicines information leaflets in hypertensive care in a setting with low health literacy: A cross-sectional study. Medicine Access Point of Care, 2020, 4, 239920262091003.	1.0	0
62	Creating clinical pharmacy capacity in Namibia: a collaboration to establish a post-graduate pharmacy degree programme. International Journal of Clinical Pharmacy, 2020, 42, 1528-1532.	1.0	0
63	Commentary on the Antidiabetic Activity of Kigelia Africana. Journal of Preventive and Rehabilitative Medicine, 2021, 3, 21-23.	0.1	0